Ask AI
ProCE Banner Activity

Advancing Frontline Strategies in BRAF-Mutant mCRC

Video

This program will explore the expanding role of biomarker-driven therapy in the frontline setting, with particular emphasis on targeted treatment approaches for patients with BRAF V600E–mutant disease. In addition to pivotal trial results, the program will address practical considerations including early and comprehensive molecular testing, interpretation of biomarker results at diagnosis, integration of targeted therapy into first-line treatment planning, and implications for subsequent sequencing.

Released: April 22, 2026